SK Bioscience Co (XKRX:302440) Total Stockholders Equity : ₩1,808,383 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is SK Bioscience Co Total Stockholders Equity?

SK Bioscience Co's Total Stockholders Equity for the quarter that ended in Mar. 2025 was ₩1,808,383 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. SK Bioscience Co's Book Value per Share for the quarter that ended in Mar. 2025 was ₩23,538.07. The ratio of a company's debt over equity can be used to measure how leveraged this company is. SK Bioscience Co's Debt-to-Equity for the quarter that ended in Mar. 2025 was 0.22.

SK Bioscience Co Total Stockholders Equity Historical Data

The historical data trend for SK Bioscience Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SK Bioscience Co Total Stockholders Equity Chart

SK Bioscience Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

Get a 7-Day Free Trial

263,790.24

1,601,311.95

1,741,702.00

1,703,855.32

1,802,565.23

SK Bioscience Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Stockholders Equity	Get a 7-Day Free Trial															1,691,536.08	1,737,790.19	1,719,441.84	1,802,565.23	1,808,382.56

SK Bioscience Co (XKRX:302440) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

SK Bioscience Co's Book Value per Share for the quarter that ended in Mar. 2025 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1808382.558	-	0)	/	76.828
	=	23,538.07

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

SK Bioscience Co's Debt-to-Equity for the quarter that ended in Mar. 2025 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6635.502	+	396544.479)	/	1808382.558
	=	0.22

SK Bioscience Co Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of SK Bioscience Co's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

SK Bioscience Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SK Bioscience Co Ltd (XKRX:302440) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

310, Pangyo-ro, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13494

Website

https://www.skbioscience.co.kr

SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.

SK Bioscience Co Headlines

No Headlines